Marizomib in Medulloblastoma: $240,000 over 2 years

Help fund this project!

We have previously identified proteasome inhibition as a promising treatment strategy for medulloblastoma. Fortuitously, this effect was seen in vivo in a conditional mouse model, despite the proteasome inhibitor only having limited blood-brain barrier (BBB) penetration. However, a second generation proteasome inhibitor that does cross the BBB, Salinosporamide-A (marizomib), is newly available. Therefore, the goal of this preclinical study is to validate marizomib as a treatment for medulloblastoma.